NICE
Sir Michael Parkinson criticises NICE
February 4, 2014Medical Communications, Sales and Marketing Astellas, NHS, NICE, Xtandi, parkinson, prostate
TV host Sir Michael Parkinson has told NICE that it must lift the restrictions imposed on Astellas’ new prostate cancer …
Roche: NICE guidance ‘perverse’
February 4, 2014Sales and Marketing NHS, NICE, NSCLC, Roche, Tarceva
Roche has poured scorn on NICE’s ‘perverse’ recommendation that its EGFR-TK inhibitor Tarceva should no longer be given to NHS …
Cancer Drugs Fund: assessing a difficult legacy
February 3, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDF, Cancer, NHS, NICE, adams, mccafferty
England’s Cancer Drugs Fund (CDF) is very good at creating division: its lobbyists say that it increases access to new …
NICE looks at Xtandi again
January 28, 2014Sales and Marketing Astellas, NHS, NICE, Xtandi
NICE has announced it is to consult again on its decision to recommend Astellas Pharma’s prostate cancer drug Xtandi after …
NICE rejects ‘benefit’ test
January 28, 2014Sales and Marketing Dillon, EMIG, NHS, NICE, benefits
NICE has refused to include a ‘wider societal benefit’ test into its deliberations about which drugs should be available on …
Mail backs down over NICE ‘champagne perks’ attack
January 24, 2014Medical Communications, Sales and Marketing Daily Mail, NHS, NICE, UK, spending
The Daily Mail newspaper has backed down on an article it published earlier this month, which alleged that staff at …
ABPI: NHS must explain drugs take-up
January 22, 2014Sales and Marketing ABPI, NHS, NICE, Whitehead
The ABPI has called on the NHS to explain what it says is the ‘substantial variation’ in NHS patients’ access …
NICE recommends Aubagio
January 22, 2014Sales and Marketing Aubagio, EU, FDA, NICE, Sanofi, gilenya
NICE has recommended Genzyme’s multiple sclerosis pill Aubagio for use on the NHS. In final guidance the watchdog said Aubagio …
NICE: Daily Mail ‘misled’ readers
January 13, 2014Sales and Marketing Dillon, NHS, NICE, mail
UK drugs watchdog NICE has hit back at an article in the Daily Mail headlined “Champagne perks of NHS drug …
NICE must get tougher on pharma, urges BMJ journal
December 16, 2013Sales and Marketing BMJ, NHS, NICE, pharma
The UK should have one universal health technology assessor which should seek to tighten up rules on whether new drugs …
NICE wants more Lemtrada data
December 6, 2013Sales and Marketing Lemtrada, MS, NICE, Sanofi
NICE has said there are ‘still questions to be answered’ over Sanofi’s submission of its multiple sclerosis drug Lemtrada and …
NICE rejects Bosulif
November 28, 2013Sales and Marketing CML, NHS, NICE, Pfizer, bosulif
In a blow for Pfizer NICE has categorically rejected the manufacturer’s Bosulif as a treatment for previously-treated chronic myeloid leukaemia …
NICE gives Lucentis more scope
November 27, 2013Sales and Marketing Lucentis, NICE, Novartis, cnv
An undisclosed price cut from Novartis has been enough to swing NICE towards using the manufacturer’s Lucentis in a fourth …
PPRS deal ‘dreadful’, says EMIG
November 26, 2013Sales and Marketing EMIG, NHS, NICE, PPRS, VBP
The Ethical Medicines Industry Group (EMIG) has slammed the new PPRS plan, calling it a ‘dreadful deal’ for its members. …
EMA looks to sharpen HTA data output
November 20, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, EMA, NICE, hta, transparency
The European Medicines Agency (EMA) has deepened its partnership with the European network for Health Technology Assessment (EUnetHTA) as it …
Latest content
FibroFind appoints Lee Borthwick as CEO
